Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: Serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival

Annals of Hematology

Volumn 84, Issue 9, 2005, Pages 594-600

  Schütt, Philipp ^a   Ebeling, Peter ^a   Buttkereit, Ulrike ^a   Brandhorst, Dieter ^a   Opalka, Bertram ^a   Poser, Miriam ^a   Müller, Siemke ^a   Flasshove, Michael ^a   Moritz, Thomas ^a   Seeber, Siegfried ^a   Nowrousian, Mohammad Resa ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Dexamethasone; Interleukin 2 receptor; Multiple myeloma; Thalidomide

Indexed keywords

ANTHRACYCLINE; ANTIBIOTIC AGENT; BETA 2 MICROGLOBULIN; DEXAMETHASONE; EPIRUBICIN; INTERLEUKIN 2 RECEPTOR; MELPHALAN; PREDNISONE; THALIDOMIDE; TUMOR MARKER; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; CONSTIPATION; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; HERPES SIMPLEX ENCEPHALITIS; HUMAN; INFECTION; LYMPHOCYTE ACTIVATION; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PERIPHERAL NEUROPATHY; PNEUMONIA; POLYNEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SEPSIS; SINUS BRADYCARDIA; SOMNOLENCE; TREATMENT OUTCOME;

AGED; CAUSE OF DEATH; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; RECEPTORS, INTERLEUKIN-2; SALVAGE THERAPY; SURVIVAL ANALYSIS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 23944512445     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-005-1007-7     Document Type: Article

References (45)

1. Akimoto Y, Ishiyama T, Ueno H, Hino K, Tomoyasu S, Tsuruoka N (1995) Clinical significance of soluble interleukin-2 receptor in multiple myeloma. Rinsho Ketsueki 36:1247-1251
2. Alexanian R, Weber D, Anagnostopoulos A, Delasalle K, Wang M, Rankin K (2003) Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Semin Hematol 40 (Suppl 4):3-7
3. Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R (2003) Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 121:768-771 10.1046/j.1365-2141.2003.04345.x
4. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335:91-97 10.1056/NEJM199607113350204
5. Cavo M, Zamagni E, Tosi P, Cellini C, Cangini D, Tacchetti P, Testoni N, Tonelli M, De Vivo A, Palareti G, Tura S, Baccarani M (2004) First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 89:826-831
6. Curley MJ, Hussein SA, Hassoun PM (2002) Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma. J Clin Microbiol 40:2302-2304
7. D'Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91:4082-4085 7513432
8. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, Treon SP, Richardson PG, Schlossman RL, Morgan GJ, Muller GW, Stirling DI, Anderson KC (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98:210-216 10.1182/blood.V98.1.210
9. Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A, Zangari M, Munshi NC, Anaissie E, Spoon D, Siegel D, Jagannath S, Vesole D, Epstein J, Shaughnessy J, Fassas A, Lim S, Roberson P, Crowley J (2000) Results of high-dose therapy for 1000 patients with multiple myeloma: Durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 95:4008-4010
10. Dimopoulos MA, Zervas K, Kouvatseas G, Galani E, Grigoraki V, Kiamouris C, Vervessou E, Samantas E, Papadimitriou C, Economou O, Gika D, Panayiotidis P, Christakis I, Anagnostopoulos N (2001) Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 12:991-995
11. Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842-854 1:STN:280:CSmD2c7kvFI%3D
12. Geitz H, Handt S, Zwingenberger K (1996) Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 31:213-221
13. Haslett P, Hempstead M, Seidman C, Diakun J, Vasquez D, Freedman VH, Kaplan G (1997) The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. AIDS Res Hum Retroviruses 13:1047-1054
14. Haslett PA, Corral LG, Albert M, Kaplan G (1998) Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 187:1885-1892 10.1084/jem.187.11.1885
15. Haslett PA, Hanekom WA, Muller G, Kaplan G (2003) Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J Infect Dis 187:946-955 10.1086/368126
16. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, Treon SP, Lin B, Schlossman RL, Richardson P, Muller G, Stirling DI, Anderson KC (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96:2943-2950
17. Hus M, Dmoszynska A, Soroka-Wojtaszko M, Jawniak D, Legiec W, Ciepnuch H, Hellmann A, Wolska-Smolen T, Skotnicki A, Manko J (2001) Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica 86:404-408
18. Juliusson G, Celsing F, Turesson I, Lenhoff S, Adriansson M, Malm C (2000) Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 109:89-96
19. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
20. Lauta VM (2001) Interleukin-6 and the network of several cytokines in multiple myeloma: An overview of clinical and experimental data. Cytokine 16:79-86
21. Lissoni P, Barni S, Rovelli F, Viviani S, Maestroni GJ, Conti A, Tancini G (1990) The biological significance of soluble interleukin-2 receptors in solid tumors. Eur J Cancer 26:33-36
22. Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170 1:STN:280:CCmC3M3htlw%3D
23. Niitsu N, Iijima K, Chizuka A (2001) A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma. Eur J Haematol 66:24-30
24. Palumbo A, Giaccone L, Bertola A, Pregno P, Bringhen S, Rus C, Triolo S, Gallo E, Pileri A, Boccadoro M (2001) Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 86:399-403 1:CAS:528:DC%2BD3MXks1ait7w%3D
25. Parman T, Wiley MJ, Wells PG (1999) Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med 5:582-585 10.1038/8466
26. Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR, Geyer S, Iturria N, Fonseca R, Lust JA, Kyle RA, Witzig TE (2002) Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20:4319-4323 10.1200/JCO.2002.02.116
27. Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, Nelson DL (1985) Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135:3172-3177 1:CAS:528:DyaL2MXlvFCksb0%3D
28. Rubin LA, Nelson DL (1990) The soluble interleukin-2 receptor: Biology, function, and clinical application. Ann Intern Med 113:619-627 1:CAS:528:DyaK3MXkt1Ohsr0%3D
29. Schutt P, Ebeling P, Buttkereit U, Brandhorst D, Opalka B, Hoiczyk M, Flasshove M, Hense J, Bojko P, Metz K, Moritz T, Seeber S, Nowrousian MR (2005) Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. Eur J Haematol 74:40-46
30. Shannon E, Aseffa A, Pankey G, Sandoval F, Lutz B (2000) Thalidomide's ability to augment the synthesis of IL-2 in vitro in HIV-infected patients is associated with the percentage of CD4+ cells in their blood. Immunopharmacology 46:175-179 10.1016/S0162-3109(99)00169-1
31. Shannon EJ, Sandoval F (1995) Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with Concanavalin-A, Staphylococcal enterotoxin A, and purified protein derivative. Immunopharmacology 31:109-116 10.1016/0162-3109(95)00039-7
32. Shannon EJ, Sandoval F, Krahenbuhl JL (1997) Hydrolysis of thalidomide abrogates its ability to enhance mononuclear cell synthesis of IL-2 as well as its ability to suppress the synthesis of TNF-alpha. Immunopharmacology 36:9-15 10.1016/S0162-3109(96)00154-3
33. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571 10.1056/NEJM199911183412102
34. Takamatsu T, Yasuda N, Ohno T, Kanoh T, Uchino H, Fujii H (1989) Soluble interleukin-2 receptors in plasma cell dyscrasias. Nippon Ketsueki Gakkai Zasshi 52:749-755
35. Tartour E, Deneux L, Mosseri V, Jaulerry C, Brunin F, Point D, Validire P, Dubray B, Fridman WH, Rodriguez J (1997) Soluble interleukin-2 receptor serum level as a predictor of locoregional control and survival for patients with head and neck carcinoma: Results of a multivariate prospective study. Cancer 79:1401-1408
36. Tartour E, Mosseri V, Jouffroy T, Deneux L, Jaulerry C, Brunin F, Fridman WH, Rodriguez J (2001) Serum soluble interleukin-2 receptor concentrations as an independent prognostic marker in head and neck cancer. Lancet 357:1263-1264
37. Tosi P, Zamagni E, Cellini C, Cangini D, Tacchetti P, Tura S, Baccarani M, Cavo M (2004) Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol 73:98-103
38. Vacca A, Di Stefano R, Frassanito A, Iodice G, Dammacco F (1991) A disturbance of the IL-2/IL-2 receptor system parallels the activity of multiple myeloma. Clin Exp Immunol 84:429-434
39. Wakao D, Murohashi I, Tominaga K, Yoshida K, Kishimoto K, Yagasaki F, Itoh Y, Itoh K, Sakata T, Kawai N, Kayano H, Suzuki T, Matsuda A, Hirashima K, Bessho M (2002) Serum thymidine kinase and soluble interleukin-2 receptor predict recurrence of malignant lymphoma. Ann Hematol 81:140-146
40. Wang LS, Chow KC, Li WY, Liu CC, Wu YC, Huang MH (2000) Clinical significance of serum soluble interleukin 2 receptor-alpha in esophageal squamous cell carcinoma. Clin Cancer Res 6:1445-1451
41. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R (2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21:16-19 10.1200/JCO.2003.03.139
42. Wolfler A, Bauer F, Zollner G, Weber K, Sill H, Linkesch W (2003) Fatal sepsis after thalidomide/dexamethasone treatment in two patients with multiple myeloma. Haematologica 88:ELT12
43. Zangari M, Barlogie B, Anaissie E, Saghafifar F, Eddlemon P, Jacobson J, Lee CK, Thertulien R, Talamo G, Thomas T, Rhee FV, Fassas A, Fink L, Tricot G (2004) Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: Effects of prophylactic and therapeutic anticoagulation. Br J Haematol 126:715-721
44. Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A, Morris C, Fink L, Tricot G (2002) Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: Implications for therapy. Blood 100:1168-1171 10.1182/blood-2002-01-0335
45. Zeimet AG, Natoli C, Herold M, Fuchs D, Windbichler G, Daxenbichler G, Iacobelli S, Dapunt O, Marth C (1996) Circulating immunostimulatory protein 90K and soluble interleukin-2-receptor in human ovarian cancer. Int J Cancer 68:34-38